J&J Will Appeal $8 Billion Verdict of Claims Risperdal Caused Breast Growth

In a statement issued last night, J&J said the verdict is “grossly disproportionate with the initial compensatory award” in the case and is confident that it will be overturned in the appeals process. The company added that the $8 billion verdict is inconsistent with other Risperdal lawsuits outside of Philadelphia. J&J said it will begin the process to set aside the verdict.